Adaptive Biotechnologies Share Price (NASDAQ: ADPT)

$13.22

▲

0.25

(1.93%)

Live

Last updated on August 28, 2025 at 11:36 pm IST

$₹

Check the interactive Adaptive Biotechnologies Stock chart to analyse performance

Adaptive Biotechnologies stock performance

as on August 28, 2025 at 11:36 pm IST

Today's Low:$13.09
Today's High:$13.29
$13.22
1.02%
Downside
Day's Volatility :1.54%
Upside
0.53%
52 Weeks Low:$3.98
52 Weeks High:$13.40
$13.22
69.89%
Downside
52 Weeks Volatility :70.28%
Upside
1.31%

Adaptive Biotechnologies Stock Returns

Period	Adaptive Biotechnologies Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	39.31%	4.2%	0.0%
6 Months	58.95%	-8.0%	0.0%
1 Year	187.58%	-12.1%	0.0%
3 Years	33.85%	7.6%	-6.9%

Adaptive Biotechnologies Corp Key Stats

Check Adaptive Biotechnologies key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$12.97
Open	$12.85
Today's High	$13.5
Today's Low	$13.085
Market Capitalization	$1.9B
Today's Volume	$1.6M
52 Week High	$13.395
52 Week Low	$3.981
Revenue TTM	$205.2M
EBITDA	$-102.8M
Earnings Per Share (EPS)	$-0.81
Profit Margin	-59.07%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-57.6%

Stock Returns calculator for Adaptive Biotechnologies Stock including INR - Dollar returns

The Adaptive Biotechnologies stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Adaptive Biotechnologies investment value today

Current value as on today

₹2,97,486

Returns

₹1,97,486

(+197.49%)

Returns from Adaptive Biotechnologies Stock

₹1,93,126 (+193.13%)

Dollar Returns*

₹4,360 (+4.36%)

Indian investors sentiment towards Adaptive Biotechnologies Stock

56%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Adaptive Biotechnologies Stock from India on INDmoney has increased by 56% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Adaptive Biotechnologies Corp

Name
Holdings %
Name
Holdings %
Viking Global Investors LP
19.70%
BlackRock Inc
8.03%
Vanguard Group Inc
7.41%
Ameriprise Financial Inc
4.36%
Rubric Capital Management LP
4.11%
Nikko Asset Management Americas Inc
4.00%

Analyst Recommendation on Adaptive Biotechnologies Stock

Rating

Trend

Buy

78%Buy

21%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Adaptive Biotechnologies(by analysts ranked 0 to 5 stars)

Adaptive Biotechnologies Share Price Target

What analysts predicted

Upside of 5.9%

Target:

$14.00

Current:

$13.22

Adaptive Biotechnologies share price target is $14.00, a slight Upside of 5.9% compared to current price of $13.22 as per analysts' prediction.

Adaptive Biotechnologies Stock Insights

Price Movement
In the last 1 month, ADPT stock has moved up by 22.2%
Increasing Revenue
Revenue is up for the last 6 quarters, 41.87M → 58.87M (in $), with an average increase of 6.5% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -33.69M → -25.61M (in $), with an average increase of 14.7% per quarter
ADPT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 115.3% return, outperforming this stock by 91.5%

Adaptive Biotechnologies Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$85.1M	↑ 52.83%
Net Income	$-58.8M	↑ 26.64%
Net Profit Margin	-69.14%	↑ 14.3%

	FY20	Y/Y Change
Revenue	$98.4M	↑ 15.65%
Net Income	$-139.6M	↑ 137.39%
Net Profit Margin	-141.93%	↓ 72.79%

	FY21	Y/Y Change
Revenue	$154.3M	↑ 56.88%
Net Income	$-205.6M	↑ 47.25%
Net Profit Margin	-133.22%	↑ 8.71%

	FY22	Y/Y Change
Revenue	$185.3M	↑ 20.06%
Net Income	$-142.5M	↓ 30.71%
Net Profit Margin	-76.88%	↑ 56.34%

	FY23	Y/Y Change
Revenue	$170.3M	↓ 8.11%
Net Income	$-225.3M	↑ 58.11%
Net Profit Margin	-132.29%	↓ 55.41%

	FY24	Y/Y Change
Revenue	$179.0M	↑ 5.1%
Net Income	$-159.5M	↓ 29.19%
Net Profit Margin	-89.12%	↑ 43.17%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$41.9M	↓ 8.54%
Net Income	$-47.5M	↓ 31.59%
Net Profit Margin	-113.45%	↑ 38.22%

	Q2 FY24	Q/Q Change
Revenue	$43.2M	↑ 3.15%
Net Income	$-46.2M	↓ 2.7%
Net Profit Margin	-107.02%	↑ 6.43%

	Q3 FY24	Q/Q Change
Revenue	$46.4M	↑ 7.51%
Net Income	$-32.1M	↓ 30.62%
Net Profit Margin	-69.07%	↑ 37.95%

	Q4 FY24	Q/Q Change
Revenue	$47.5M	↑ 2.21%
Net Income	$-33.7M	↑ 5.05%
Net Profit Margin	-70.99%	↓ 1.92%

	Q1 FY25	Q/Q Change
Revenue	$52.4M	↑ 10.5%
Net Income	$-29.9M	↓ 11.4%
Net Profit Margin	-56.92%	↑ 14.07%

	Q2 FY25	Q/Q Change
Revenue	$58.9M	↑ 12.27%
Net Income	$-25.6M	↓ 14.2%
Net Profit Margin	-43.5%	↑ 13.42%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$62.8M	↑ 74.46%

	FY20	Y/Y Change
Profit	$75.9M	↑ 20.79%

	FY21	Y/Y Change
Profit	$105.0M	↑ 38.48%

	FY22	Y/Y Change
Profit	$127.4M	↑ 21.28%

	FY23	Y/Y Change
Profit	$94.7M	↓ 25.65%

	FY24	Y/Y Change
Profit	$106.9M	↑ 12.83%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$23.8M	↑ 14.66%

	Q2 FY24	Q/Q Change
Profit	$21.1M	↓ 11.48%

	Q3 FY24	Q/Q Change
Profit	$29.8M	↑ 41.16%

	Q4 FY24	Q/Q Change
Profit	$29.4M	↓ 1.19%

	Q1 FY25	Q/Q Change
Profit	$35.5M	↑ 20.57%

	Q2 FY25	Q/Q Change
Profit	$40.9M	↑ 15.27%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$205.4M	↓ 736.73%
Investing Cash Flow	$-481.7M	↓ 65547.96%
Financing Cash Flow	$319.9M	↑ 25534.29%

	FY20	Y/Y Change
Operating Cash Flow	$-149.7M	↓ 172.87%
Investing Cash Flow	$-117.0M	↓ 75.7%
Financing Cash Flow	$293.6M	↓ 8.23%

	FY21	Y/Y Change
Operating Cash Flow	$-192.7M	↑ 28.76%
Investing Cash Flow	$181.2M	↓ 254.82%
Financing Cash Flow	$27.1M	↓ 90.75%

	FY22	Y/Y Change
Operating Cash Flow	$-183.9M	↓ 4.56%
Investing Cash Flow	$2.9M	↓ 98.4%
Financing Cash Flow	$132.3M	↑ 387.24%

	FY23	Y/Y Change
Operating Cash Flow	$-156.3M	↓ 15.02%
Investing Cash Flow	$129.6M	↑ 4362.89%
Financing Cash Flow	$2.2M	↓ 98.3%

	FY24	Y/Y Change
Operating Cash Flow	$-95.2M	↓ 39.09%
Investing Cash Flow	$77.8M	↓ 40.0%
Financing Cash Flow	$241.0K	↓ 89.27%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-38.4M	↑ 42.41%
Investing Cash Flow	$44.5M	↑ 1287.87%
Financing Cash Flow	$44.0K	↓ 49.43%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-17.3M	↓ 54.88%
Investing Cash Flow	$5.9M	↓ 86.8%
Financing Cash Flow	$30.0K	↓ 31.82%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-27.1M	↑ 56.42%
Investing Cash Flow	$5.3M	↓ 10.04%
Financing Cash Flow	$40.0K	↑ 33.33%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-12.5M	↓ 53.85%
Investing Cash Flow	$22.1M	↑ 318.37%
Financing Cash Flow	$127.0K	↑ 217.5%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-28.5M	↑ 128.04%
Investing Cash Flow	$25.6M	↑ 15.62%
Financing Cash Flow	$5.5M	↑ 4192.13%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-12.4M	↓ 56.36%
Investing Cash Flow	$3.3M	↓ 86.92%
Financing Cash Flow	$1.6M	↓ 70.46%

Adaptive Biotechnologies Technicals Summary

Sell

Neutral

Buy

Adaptive Biotechnologies is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Adaptive Biotechnologies Corp Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adaptive Biotechnologies Corp	24.83%	58.95%	187.58%	33.85%	-68.83%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.48%	-51.06%	-0.98%	-5.32%
Beone Medicines Ltd	-1.83%	7.82%	51.46%	79.4%	24.25%
Vertex Pharmaceuticals Incorporated	-16.94%	-18.0%	-20.55%	38.17%	39.4%
Alnylam Pharmaceuticals, Inc.	37.4%	91.56%	61.8%	117.28%	242.42%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adaptive Biotechnologies Corp	NA	NA	0.0	-0.72	-0.58	-0.14	NA	1.18
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.58	27.58	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adaptive Biotechnologies Corp	Buy	$1.9B	-68.83%	NA	-59.07%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-5.32%	14.86	31.37%
Beone Medicines Ltd	NA	$37.7B	24.25%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.3B	39.4%	27.58	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	242.42%	NA	-12.96%

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Organization	Adaptive Biotechnologies
Employees	619
CEO	Mr. Chad M. Robins M.B.A.
Industry	Commercial Services

Key Management of Adaptive Biotechnologies Corp

Name	Title
Mr. Chad M. Robins M.B.A.	Co-Founder, CEO & Chairman
Ms. Julie Rubinstein	President & COO
Dr. Harlan S. Robins Ph.D.	Co-Founder & Chief Scientific Officer
Mr. Kyle Piskel	VP, CFO & Principal Accounting Officer
Dr. Sharon Benzeno Ph.D.	Chief Commercial Officer of Immune Medicine
Mr. Christopher Carlson Ph.D.	Founder
Ms. Karina Calzadilla	Vice President of Investor Relations
Ms. Clarice McCauley	Interim General Counsel, Corporate Secretary, VP & Chief Compliance Officer
Mr. Francis T. Lo	Chief People Officer
Ms. Susan Bobulsky	Chief Commercial Officer of MRD

Important FAQs about investing in ADPT Stock from India :

What is Adaptive Biotechnologies share price today?

Adaptive Biotechnologies share price today is $13.22 as on August 28, 2025 at 11:36 pm IST. Adaptive Biotechnologies share today touched a day high of $13.29 and a low of $13.09.

What is the 52 week high and 52 week low for Adaptive Biotechnologies share?

Adaptive Biotechnologies share touched a 52 week high of $13.40 and a 52 week low of $3.98. Adaptive Biotechnologies stock price today i.e. August 28, 2025 at 11:36 pm IST is trending at $13.22, lower by 1.31% versus the 52 week high.

How to invest in Adaptive Biotechnologies Stock (ADPT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Adaptive Biotechnologies on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Adaptive Biotechnologies Shares that will get you 0.1135 shares as per Adaptive Biotechnologies share price of $13.22 per share as on August 28, 2025 at 11:36 pm IST.

What is the minimum amount required to buy Adaptive Biotechnologies Stock (ADPT) from India?

Indian investors can start investing in Adaptive Biotechnologies (ADPT) shares with as little as ₹87.587 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.87 in Adaptive Biotechnologies stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Adaptive Biotechnologies share’s latest price of $13.22 as on August 28, 2025 at 11:36 pm IST, you will get 0.7564 shares of Adaptive Biotechnologies. Learn more about fractional shares .

What are the returns that Adaptive Biotechnologies has given to Indian investors in the last 5 years?

Adaptive Biotechnologies stock has given -68.83% share price returns and 18.52% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?